# Cullinan Therapeutics, Inc. (CGEM) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/CGEM
## Company Profile
- Ticker: CGEM
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 17.95 USD
- Market cap: 942766425.64 USD
- Last updated: 2026-08-06
## Business Overview
### Autoimmune and Oncology Therapeutics
Cullinan Therapeutics develops targeted therapies and immune-cell engagers across autoimmune disease and cancer.
### CLN-978
CLN-978 is a compact CD19-directed T-cell engager designed to deplete B cells. It is being studied in systemic lupus erythematosus and rheumatoid arthritis, including multi-dose evaluation.
### Zipalertinib
Zipalertinib is an oral EGFR inhibitor under FDA review for previously treated EGFR exon 20 insertion-positive non-small cell lung cancer.
### Velinotamig
Velinotamig is a BCMA-directed T-cell engager in clinical development for multiple myeloma.
## Why The Stock Is Moving

The latest company update was “Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results”. CGEM changed 1.93% and closed at $17.95 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this earnings update.

## Future Catalysts

- Initial CLN-978 data in lupus and rheumatoid arthritis at EULAR 2026.
- Multi-dose rheumatoid-arthritis data for CLN-978 in the third quarter of 2026.
- Additional clinical data for velinotamig during 2026.
- PDUFA target action date for zipalertinib on February 27, 2027.

## Recent News
- 2026-08-06 11:00 EST — [Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-provides-corporate-update-and-reports-second-quarter-2026--3ee8752a) — Source: Cullinan Therapeutics, Inc.
- 2026-07-28 11:00 EST — [Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML](https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-announces-positive-end-of-phase-1-meeting-with-fda-for-cln-68006175) — Source: Cullinan Therapeutics, Inc.
- 2026-06-10 11:30 EST — [Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases](https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-shares-new-clinical-data-across-its-portfolio-of-t-cell-en-1824446e) — Source: Cullinan Therapeutics, Inc.
- 2026-06-06 09:15 EST — [Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress](https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-presents-initial-clinical-data-for-cln-978-a-cd19xcd3-t-ce-5c413068) — Source: Cullinan Therapeutics, Inc.
- 2026-05-26 11:00 EST — [Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager](https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-to-host-immunology-day-to-showcase-promising-initial-clini-cc2e30f1) — Source: Cullinan Therapeutics, Inc.